APEIRON Announces Collaboration with Lead Discovery Center GmbH

Alliance for medicinal chemistry optimization and development of novel checkpoint blockade approach. Press release Presseaussendung

September 20, 2018
View the Post

APEIRON Appoints Peter Llewellyn-Davies as Chief Executive Officer

The former CEO Dr. Hans Loibner will continue to support the Company as senior advisor. Press release Presseaussendung  

July 17, 2018
View the Post

APEIRON, the Medical University of Vienna and the Institute of Molecular Biotechnology Sign Licensing Agreement for a New Checkpoint Inhibitor.

APEIRON strengthens its proprietary Cbl-b portfolio with cutting edge immunotherapy technology developed at IMBA. Presseaussendung Press Release

July 2, 2018
View the Post